Kenney Daniel M, Geschwindt Ryan D, Kary Marcia R, Linic Jeanette M, Sardesai Niranjan Y, Li Zhong-Qian
Departments of Applied Research and Product Development, Fujirebio Diagnostics, Inc., Malvern, Pa., USA.
Tumour Biol. 2007;28(2):57-62. doi: 10.1159/000099033. Epub 2007 Jan 26.
BACKGROUND/AIMS: Survivin mRNA in urine was measured to detect newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria.
We have investigated urinary survivin mRNA of 118 voided urine specimens, including 24 patients with bladder cancer, 50 with bladder cancer history, 68 not known to harbor bladder cancer, and 55 with hematuria using quantitative reverse transcriptase polymerase chain reaction. beta-Actin mRNA expression was also examined and used as an endogenous control to ensure validity of the assay for each sample.
The survivin expression in urological patient urine had sensitivities and specificities for all patients of 79 and 93%, for detection of newly diagnosed bladder cancer 83 and 95%, for bladder cancer recurrence 82 and 90%, and for bladder cancer in patients with hematuria 80 and 90%.
Our results indicate that quantitative reverse transcriptase polymerase chain reaction of urinary survivin is a sensitive, noninvasive and highly specific assay to detect both newly diagnosed bladder cancer and bladder cancer recurrence. Furthermore, this assay may be useful in stratifying the hematuria population in urological practice.
背景/目的：检测尿液中的生存素信使核糖核酸（Survivin mRNA），以诊断新确诊的膀胱癌、膀胱癌复发以及血尿患者中的膀胱癌。
我们使用定量逆转录聚合酶链反应，对118份晨尿样本中的尿液生存素信使核糖核酸进行了研究，这些样本包括24例膀胱癌患者、50例有膀胱癌病史的患者、68例未知患有膀胱癌的患者以及55例血尿患者。还检测了β-肌动蛋白信使核糖核酸的表达，并将其用作内源性对照，以确保每个样本检测方法的有效性。
泌尿系统疾病患者尿液中的生存素表达对所有患者的敏感性和特异性分别为79%和93%，对新确诊膀胱癌的检测敏感性和特异性分别为83%和95%，对膀胱癌复发的检测敏感性和特异性分别为82%和90%，对血尿患者中膀胱癌的检测敏感性和特异性分别为80%和90%。
我们的结果表明，尿液生存素的定量逆转录聚合酶链反应是一种检测新确诊膀胱癌和膀胱癌复发的敏感、无创且高度特异的检测方法。此外，该检测方法可能有助于在泌尿外科实践中对血尿人群进行分层。
